ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split
August 29, 2024 16:50 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced completion of the merger with Oruka Therapeutics, Inc. (“Oruka”) following ARCA’s...
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
August 16, 2024 16:15 ET
|
ARCA biopharma, Inc.
Special dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka WESTMINSTER, Colo., Aug. 16, 2024 (GLOBE...
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 01, 2024 16:15 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing...
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
April 25, 2024 16:15 ET
|
ARCA biopharma, Inc.
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
ARCA biopharma Announces Second Quarter 2023 Financial Results
July 21, 2023 16:25 ET
|
ARCA biopharma, Inc.
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., July 21, 2023 (GLOBE...